We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
Read MoreHide Full Article
ADMA Biologics’ (ADMA - Free Report) shares have lost 8.9% in a month against the industry’s growth of 6.6%.
The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.
Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.
ADMA Underperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’ Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Demand was record high in 2024 with further growth expected in 2025 with further penetration. ADMA Biologics executed multiple, long-term third-party plasma supply contracts, which should contribute to a continuous and growing supply of high-titer plasma expected to meet Asceniv’s growth targets through the late 2030s. Management anticipated these supply agreements to position ADMA to potentially achieve $1 billion in total annual revenues before 2030, with significant growth potential in the 2030s.
ADMA’s Efforts to Expand Asceniv’s Label
In connection with the FDA’s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide an opportunity for label expansion to include pediatric-aged PI patients.
All pediatric patients in Asceniv’s post-marketing pediatric study have now completed their treatment schedule. ADMA expects to file its supplemental biologics license application over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion should strengthen ADMA’s product portfolio.
ADMA’s Financial Targets
Along with providing preliminary results, ADMA provided its outlook for 2025 and 2026. ADMA now expects to generate revenues of more than $485 million in 2025 and $600 million in 2026 (previous guidance: more than $465 million in 2025). Net income is projected to exceed $170 million in 2025 and $230 million in 2026 (up from the prior guidance of $165 million for 2025).
Margin Improvement
ADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.
Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 8.21x forward sales, higher than its mean of 3.31x and the industry’s 1.71x.
Image Source: Zacks Investment Research
Estimate Movement
The estimate for 2024 and 2025 EPS has moved down 1 cent and 3 cents, respectively, to 51 cents and 60 cents over the past 30 days.
Image Source: Zacks Investment Research
Stay Invested in ADMA Stock
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
The targeted market has significant growth potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
However, the exceptional rally witnessed by the stock might limit any further gain. We advise investors to wait for now. For investors already owning the stock, staying invested would be a prudent move.
Image: Bigstock
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
ADMA Biologics’ (ADMA - Free Report) shares have lost 8.9% in a month against the industry’s growth of 6.6%.
The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.
Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.
ADMA Underperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’ Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Demand was record high in 2024 with further growth expected in 2025 with further penetration. ADMA Biologics executed multiple, long-term third-party plasma supply contracts, which should contribute to a continuous and growing supply of high-titer plasma expected to meet Asceniv’s growth targets through the late 2030s. Management anticipated these supply agreements to position ADMA to potentially achieve $1 billion in total annual revenues before 2030, with significant growth potential in the 2030s.
ADMA’s Efforts to Expand Asceniv’s Label
In connection with the FDA’s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide an opportunity for label expansion to include pediatric-aged PI patients.
All pediatric patients in Asceniv’s post-marketing pediatric study have now completed their treatment schedule. ADMA expects to file its supplemental biologics license application over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion should strengthen ADMA’s product portfolio.
ADMA’s Financial Targets
Along with providing preliminary results, ADMA provided its outlook for 2025 and 2026. ADMA now expects to generate revenues of more than $485 million in 2025 and $600 million in 2026 (previous guidance: more than $465 million in 2025). Net income is projected to exceed $170 million in 2025 and $230 million in 2026 (up from the prior guidance of $165 million for 2025).
Margin Improvement
ADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.
Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 8.21x forward sales, higher than its mean of 3.31x and the industry’s 1.71x.
Image Source: Zacks Investment Research
Estimate Movement
The estimate for 2024 and 2025 EPS has moved down 1 cent and 3 cents, respectively, to 51 cents and 60 cents over the past 30 days.
Image Source: Zacks Investment Research
Stay Invested in ADMA Stock
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
The targeted market has significant growth potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
However, the exceptional rally witnessed by the stock might limit any further gain. We advise investors to wait for now. For investors already owning the stock, staying invested would be a prudent move.
ADMA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.